Oramed Pharmaceuticals Inc. revenue

Revenue history

AnnualQuarterly

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Oramed Pharmaceuticals Inc.: revenue history, annual

Fiscal year	2016Aug 2016	2017Aug 2017	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Revenue	641	2,456	2,449	2,703	2,710	2,703	2,703	1,340	2,000
Growth on the year before	—	+283.2%	−0.3%	+10.4%	+0.3%	−0.3%	0.0%	−50.4%	+49.3%
Gross profit	151	2,269	2,535	2,613	—	—	—	—	13
Gross margin	23.6%	92.4%	—	96.7%	—	—	—	—	0.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Oramed Pharmaceuticals Inc.	$2.0m	-50.4%	-9.5%
Korsana Biosciences, Inc.	$1.9m	-12.6%	—
Seres Therapeutics, Inc.	$1.9m	100.0%	-75.6%
Collplant Biotechnologies Ltd	$2.4m	360.4%	—
Korro Bio, Inc.	$2.4m	-62.1%	-53.7%
Vistagen Therapeutics, Inc.	$2.5m	287.3%	—

Compare with peers

• Korsana Biosciences, Inc. revenue
• Seres Therapeutics, Inc. revenue
• Collplant Biotechnologies Ltd revenue
• Korro Bio, Inc. revenue
• Vistagen Therapeutics, Inc. revenue

Head to head: KRSA vs ORMPMCRB vs ORMPCLGN vs ORMP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Oramed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Oramed Pharmaceuticals Inc.